From data to deployment: Navigating AI adoption in pharma with Veeva

On the power of T-cells, with Cedrik Britten

Why everyone should care about longevity, with Boyang Wang

A philosophical look at market turn in the Age of AI, with John Holodnak

Providing patient access to new therapies, with Dean Erhardt

LSX2026: Endogenous tissue restoration in vascular disease – Insights from Paulo Neves

Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja

Every drug is a story, with Thomas Goetz

LSX2026: Non-opioid pain relief and pharma positivity, with Mike Cooke

LSX2026: Addressing adult eye cancer, with Roi Raz

Making direct-to-patient work, with Matt Wadyka

Looking to gene therapy for ocular diseases, with Lance Baldo

Biotech is back, with Craig Ackerman

LSX2026: On a therapeutic vision for ocular disease, with Alexander Gebauer

LSX2026: On promise and patience, with Hans Schambye

Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq

BIO-Europe Spring 2026: In conversation with Marjorie Sidhoum

Hernexeos and what’s next, with Vicky Brown

On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan

Using patient data to fill in GLP-1 blind spots, with Phil Johnson

BIO-Europe Spring 2026: In conversation with Robert Jacks

Making AI work where it matters, with Rob DiCicco

Treating genetic disease at scale with tRNA, with Michelle Werner

AI in clinical development & ‘white space’, with Andrew Mackinnon

Collaboration & personalisation in rare disease R&D, with AOP Health’s Melissa Fellner

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran

On JPM2026 and healthcare investment today, with Jonah Comstock

New hope for ovarian cancer, with Alexander Schneider

Precision medicine in action, with Cary Claiborne

On addressing drug waste and ensuring access, with Jeff Harper

Treating the chronic diseases GLP-1s miss, with Laurent Audaly

The long-delayed promise of the microbiome, with Sam Possemiers

From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast

A cancer treatment modality that prioritises QoL, with Ben Zeskind

On quality data for quality learnings, with Lisa Sims

Allogeneic cell therapy isn’t dead, with Brian Culley

Engineering “smarter” cells, with Tim Lu

JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe

DNA as a programmable language, with Adrian Woolfson and Kaihang Wang #dna #genyro #breakingnews

The secrets of the secretome, with Hans Keirstead

STEM AI: Delivering intelligent data-led HCP interactions

Astellas’s banner year and focused R&D strategy, with Adam Pearson

On AI and equity in the cancer setting, with Mohit Manrao

Bringing parity to infertility, with Jean Duvall

Rewiring commercialisation to meet the moment, with Helen Sabzevari and Greg Skalicky

JPM2026: AI diagnostics and translational research, with Andrew Beck

Unlocking the future of epigenetics, with Carlos Buesa

Is this the year for precision psychology? With Amit Etkin

Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf

Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland

Rethinking prescription drug affordability, with Vinay Patel

An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad

On genomics, NGS, and doing much more good than bad, with Markus Vossman

Delivering the right behavioural ingredients for the moment, with Amy Bucher

AI for the planet, AI for life sciences – with Patrick Leung

On the future of AI in life sciences, with women at the helm

Unlocking the future of obesity treatment

On AI and computational support of biochemistry, with Alan Roth

Harnessing the cell's own degradation machinery, with Benedict Cross

How blood tests can inform cancer treatment decisions, with Craig Eagle